Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01764256 · ClinicalTrials.gov registry record · Phase 1

A Phase 1 Dose Escalation Study to Examine the Safety of the P2-VP8 Rotavirus Vaccine

A Phase 1 study, sponsored by PATH.

Completed
Registry status
Phase 1
Development phase
48
Enrollment target

NCT01764256 is a Phase 1 study that has completed, run by PATH. The registered enrollment target is 48 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01764256, a Phase 1 study, has completed, sponsored by PATH.

COMPLETED
Registry status
Phase 1
Development phase
48 participants
Enrollment target

Study Summary

This study will evaluate 3 doses of a new vaccine for rotavirus infection in healthy adult volunteers to determine if it is safe and if the immune systems of healthy adults respond to this vaccine.

Interventions

  • OTHER placebo
  • BIOLOGICAL P2-VP8 subunit rotavirus vaccine

Trial Details

FieldValue
Enrollment Target 48 participants
Start Date 2012-12
Est. Completion 2013-09
Phase Phase 1

Sponsor

PATH

18 total trials

What the Registry Record Tells You About NCT01764256

The ClinicalTrials.gov registry entry for NCT01764256 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is PATH, which has 18 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.

NCT01764256 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT01764256 about?

NCT01764256 is a clinical study titled "A Phase 1 Dose Escalation Study to Examine the Safety of the P2-VP8 Rotavirus Vaccine". This study will evaluate 3 doses of a new vaccine for rotavirus infection in healthy adult volunteers to determine if it is safe and if the immune systems of healthy adults respond to this vaccine.

What is the current status of trial NCT01764256?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2012-12. Estimated completion is 2013-09.

What interventions are being tested in trial NCT01764256?

The interventions under investigation include: placebo (OTHER), P2-VP8 subunit rotavirus vaccine (BIOLOGICAL).

Who is sponsoring clinical trial NCT01764256?

This trial is sponsored by PATH, which has 18 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.